BioNTech SE (NASDAQ:BNTX) Receives $231.43 Average PT From Analysts
BioNTech SE (NASDAQ:BNTX) Receives $231.43 Average PT From Analysts
BioNTech SE (NASDAQ:BNTX – Get Rating) has been given a consensus rating of "Hold" by the seventeen analysts that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $231.43.
據MarketBeat Ratings報道，目前追蹤該股的17位分析師一致給予BioNTech SE(納斯達克股票代碼：BNTX-GET Rating)“持有”的評級。五名分析師對該股的評級為持有建議，四名分析師對該公司發出了買入建議。在去年更新了對該股覆蓋範圍的經紀商中，12個月的平均目標價為231.43美元。
Several analysts recently issued reports on BNTX shares. The Goldman Sachs Group set a $200.00 price target on shares of BioNTech in a research report on Tuesday, August 9th. Cowen started coverage on shares of BioNTech in a research report on Wednesday, August 17th. They issued a "market perform" rating and a $177.00 target price on the stock. Canaccord Genuity Group raised their target price on shares of BioNTech from $192.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, August 9th. Canaccord Genuity Group restated a "buy" rating and issued a $192.00 target price on shares of BioNTech in a research report on Wednesday, July 6th. Finally, UBS Group set a $168.00 target price on shares of BioNTech in a research report on Thursday, June 30th.
幾位分析師最近發佈了有關BNTX股票的報告。高盛在8月9日週二的一份研究報告中為生物技術公司的股票設定了200.00美元的目標價。考恩在8月17日星期三的一份研究報告中開始報道BioNTech的股票。他們對該股給予了“市場表現”評級和177.00美元的目標價。8月9日，在一份研究報告中，Cancord Genuity Group將BioNTech的股票目標價從192.00美元上調至200.00美元，並給予該公司“買入”評級。7月6日，在一份研究報告中，CANACCORD GENINITY集團重申了買入評級，併為BioNTech的股票設定了192.00美元的目標價。最後，瑞銀集團在6月30日星期四的一份研究報告中為BioNTech的股票設定了168.00美元的目標價。
BioNTech Trading Down 1.3 %
BioNTech股價下跌1.3%
Shares of NASDAQ:BNTX opened at $128.35 on Monday. BioNTech has a 52-week low of $117.08 and a 52-week high of $374.58. The company has a market capitalization of $31.15 billion, a P/E ratio of 2.48 and a beta of 0.03. The company has a 50-day simple moving average of $152.89 and a 200 day simple moving average of $154.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.06 and a current ratio of 5.15.
納斯達克：BNTX週一開盤報128.35美元。BioNTech的52周低點為117.08美元，52周高位為374.58美元。該公司市值為311.5億美元，市盈率為2.48倍，貝塔係數為0.03。該公司的50日簡單移動均線切入位在152.89美元，200日簡單移動均線切入位在154.75美元。該公司的負債權益比率為0.01，速動比率為5.06，流動比率為5.15。
Institutional Investors Weigh In On BioNTech
機構投資者買入BioNTech
Several hedge funds and other institutional investors have recently made changes to their positions in BNTX. Captrust Financial Advisors boosted its stake in BioNTech by 6.9% in the second quarter. Captrust Financial Advisors now owns 1,068 shares of the company's stock valued at $159,000 after acquiring an additional 69 shares during the last quarter. Centaurus Financial Inc. boosted its stake in shares of BioNTech by 5.2% in the 1st quarter. Centaurus Financial Inc. now owns 1,448 shares of the company's stock valued at $247,000 after purchasing an additional 71 shares in the last quarter. Exane Derivatives boosted its stake in shares of BioNTech by 13.5% in the 2nd quarter. Exane Derivatives now owns 799 shares of the company's stock valued at $119,000 after purchasing an additional 95 shares in the last quarter. KRS Capital Management LLC purchased a new stake in shares of BioNTech in the 4th quarter valued at $25,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in BioNTech by 66.7% during the 1st quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 250 shares of the company's stock valued at $43,000 after buying an additional 100 shares during the period. 13.77% of the stock is owned by institutional investors.
幾家對衝基金和其他機構投資者最近改變了他們在BNTX的頭寸。CapTrust Financial Advisors在第二季度將其在BioNTech的持股增加了6.9%。CapTrust Financial Advisors在上個季度增持了69股後，現在擁有1,068股該公司股票，價值15.9萬美元。今年第一季度，Centaurus Financial Inc.增持了BioNTech的股份5.2%。半人馬座金融公司目前持有1,448股該公司股票，價值24.7萬美元，該公司在上個季度又購買了71股。Exane衍生品在第二季度將其在BioNTech的股份增加了13.5%。Exane衍生品現在擁有該公司799股股票，價值11.9萬美元，此前在上個季度又購買了95股。KRS Capital Management LLC在第四季度購買了BioNTech的新股，價值25,000美元。最後，洛林·沃爾科特和柯立芝信託顧問公司LLP MA在第一季度將其在BioNTech的頭寸提高了66.7%。洛林·沃爾科特和柯立芝信託顧問公司現在擁有250股該公司的股票，價值43,000美元，在此期間又購買了100股。13.77%的股份由機構投資者持有。
About BioNTech
關於BioNTech
(Get Rating)
(獲取評級)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
BioNTech SE是一家生物技術公司，開發和銷售治療癌症和其他傳染病的免疫療法。該公司正在開發FixVac候選產品，包括治療晚期黑色素瘤的第二階段臨牀試驗的BNT111、治療前列腺癌的第一階段/第二階段臨牀試驗的BNT112、治療HPV陽性頭頸癌的第二階段臨牀試驗的BNT113、治療三陰性乳腺癌的第一階段臨牀試驗的BNT114、治療卵巢癌的第一階段臨牀試驗的BNT115以及治療非小細胞肺癌的臨牀前階段產品BNT116。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on BioNTech (BNTX)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 免費獲取StockNews.com關於BioNTech的研究報告(BNTX)
- MarketBeat：回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性？
- 需要關注的2只半導體類股走勢逆轉
- CrowdStrike是否會從增加每股收益指引中獲得提振？
- 小盤股的裁員是樓市的晴雨表嗎？
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《BioNTech Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioNTech和相關公司的最新新聞和分析師評級的每日簡要摘要。